Published in Dig Dis Sci on June 01, 2004
Acute Pancreatitis Associated with Pegylated Interferon and Ribavirin Treatment of Chronic Hepatitis C, Genotype 1b with High Viral Load. Case Rep Gastroenterol (2009) 0.93
Acute pancreatitis during interferon-alpha and ribavirin treatment for hepatitis C. BMJ Case Rep (2009) 0.90
Risk of pancreatic cancer among individuals with hepatitis C or hepatitis B virus infection: a nationwide study in Sweden. Br J Cancer (2013) 0.85
Increased Risk of Acute Pancreatitis in Patients with Rheumatoid Arthritis: A Population-Based Cohort Study. PLoS One (2015) 0.76
Comparison of the chronic effects of ribavirin and caffeic acid phenethyl ester (CAPE) on pancreatic damage and hepatotoxicity. Int J Clin Exp Med (2014) 0.75
Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C. Clin Mol Hepatol (2016) 0.75
Loss of Ifnar1 in Pancreatic Acinar Cells Ameliorates the Disease Course of Acute Pancreatitis. PLoS One (2015) 0.75
Association of use of selective serotonin reuptake inhibitors with risk of acute pancreatitis: a case-control study in Taiwan. Eur J Clin Pharmacol (2017) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med (1999) 16.35
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med (1995) 5.98
Acute pancreatitis. N Engl J Med (1994) 5.32
Drug-induced pancreatitis: a critical review. Gastroenterology (1980) 3.21
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02
Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1995) 2.49
Side effects of therapy for chronic hepatitis C. Gastroenterology (2003) 2.04
Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology (1997) 1.77
Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol (1996) 1.73
Ribavirin--current status of a broad spectrum antiviral agent. Expert Opin Pharmacother (2001) 1.70
Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology (1997) 1.51
Management of severe acute pancreatitis. Br J Surg (2003) 1.39
Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther (1999) 1.31
Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology (1997) 1.03
Review article: drug-induced pancreatitis. Aliment Pharmacol Ther (1996) 1.03
Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther (2002) 0.97
Acute pancreatitis attributed to the use of interferon alfa-2b. Gastroenterology (2000) 0.92
Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. Am J Gastroenterol (2001) 0.92
Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. Hepatology (1999) 0.91
Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat (1996) 0.85
Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia. Leuk Lymphoma (2000) 0.83
Acute pancreatitis associated with interferon-alpha therapy for chronic myelogenous leukemia. Am J Hematol (1995) 0.82
Lipoprotein changes in patients with chronic hepatitis C treated with interferon-alpha. Am J Gastroenterol (1998) 0.77
Differential effects of nucleoside analogs on oxidative phosphorylation in human pancreatic cells. Dig Dis Sci (2001) 0.75
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Bacterial biota in the human distal esophagus. Proc Natl Acad Sci U S A (2004) 5.64
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med (2005) 2.95
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Prospective comparison of patient experience with colon imaging tests. Am J Med (2006) 2.42
Multicenter, randomized, controlled trial of virtual-reality simulator training in acquisition of competency in colonoscopy. Gastrointest Endosc (2006) 2.33
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology (2005) 2.21
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol (2004) 2.12
Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol (2003) 1.95
Colorectal cancer screening in HIV-infected patients 50 years of age and older: missed opportunities for prevention. Am J Gastroenterol (2005) 1.94
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol (2003) 1.83
Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat (2006) 1.81
Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis (2008) 1.78
Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology (2006) 1.70
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology (2010) 1.70
Prevalence and predictors of herbal medication use in veterans with chronic hepatitis C. J Clin Gastroenterol (2004) 1.48
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol (2004) 1.47
Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing. J Gen Intern Med (2005) 1.46
U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients. Dig Dis Sci (2011) 1.44
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43
Prevalence and impact of extracolonic findings in patients undergoing CT colonography. J Clin Gastroenterol (2004) 1.42
Colon pathology detected after a positive screening flexible sigmoidoscopy: a prospective study in an ethnically diverse cohort. Am J Gastroenterol (2006) 1.41
Acute HIV seroconversion in a patient receiving pegylated interferon for treatment of hepatitis C. AIDS Read (2003) 1.38
Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1. AIDS Read (2006) 1.38
Colorectal neoplasms: prospective comparison of thin-section low-dose multi-detector row CT colonography and conventional colonoscopy for detection. Radiology (2002) 1.32
Liver transplantation in alcoholic liver disease current status and controversies. World J Gastroenterol (2013) 1.30
Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older. Arch Intern Med (2006) 1.30
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology (2004) 1.30
Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol (2008) 1.29
Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs. Public Health Rep (2007) 1.29
Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol (2013) 1.25
Endoscopy plays an important preoperative role in bariatric surgery. Obes Surg (2004) 1.23
Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. World J Gastroenterol (2009) 1.22
Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy. J Clin Gastroenterol (2007) 1.22
Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. Hepatology (2005) 1.21
Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology (2006) 1.20
Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol (2005) 1.17
Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. Hepatology (2012) 1.15
Helicobacter pylori and overweight status in the United States: data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol (2005) 1.13
Increasing plasmalogen levels protects human endothelial cells during hypoxia. Am J Physiol Heart Circ Physiol (2002) 1.10
Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses (2010) 1.08
Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis (2012) 1.08
Receiver operating characteristic analysis: a general tool for DNA array data filtration and performance estimation. Genomics (2003) 1.08
Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS (2005) 1.08
Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology (2002) 1.05
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J Thromb Thrombolysis (2010) 1.03
Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol (2006) 1.03
CT colonography: where have we been and where are we going? Radiology (2005) 1.03
A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol (2005) 1.02
States and substance abuse treatment programs: funding and guidelines for infection-related services. Am J Public Health (2008) 1.01
Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol (2005) 1.01
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis (2003) 1.00
High prevalence of hepatitis C virus infection among immigrants from the former Soviet Union in the New York City metropolitan area: results of a community-based screening program. Am J Gastroenterol (2008) 0.99
Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice? J Clin Gastroenterol (2008) 0.99
Definition, epidemiology and magnitude of alcoholic hepatitis. World J Hepatol (2011) 0.99
Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter? J Clin Gastroenterol (2007) 0.99
Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol (2002) 0.97
Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig Dis Sci (2011) 0.97
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr (2008) 0.97
HIV and liver diseases: recent clinical advances. Clin Liver Dis (2005) 0.96
Endoscopic band ligation of bleeding rectal varices. Dig Dis Sci (2002) 0.96
Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr (2004) 0.95
Management of chronic hepatitis C virus in patients with HIV. Curr Treat Options Gastroenterol (2005) 0.95
Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: a proposed diagnostic algorithm. J Infect Dis (2013) 0.94
The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV. Virchows Arch (2010) 0.93
HIV/hepatitis C virus-coinfected patients and cirrhosis: how to diagnose it and what to do next? Clin Infect Dis (2013) 0.93
Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life. Am J Gastroenterol (2006) 0.93
Colorectal polyps and cancers in asymptomatic average-risk patients: evaluation with CT colonography. Radiology (2004) 0.92
Radiologic assessment of the upper gastrointestinal tract: does it play an important preoperative role in bariatric surgery? Obes Surg (2004) 0.92
Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women. Int J Cardiol (2010) 0.91
Hepatitis C virus infection in alcoholic hepatitis: prevalence patterns and impact on in-hospital mortality. Eur J Gastroenterol Hepatol (2012) 0.90
Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis (2013) 0.90
Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr (2002) 0.89
Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis (2012) 0.88
Genetic analysis of interferon induced thyroiditis (IIT): evidence for a key role for MHC and apoptosis related genes and pathways. J Autoimmun (2013) 0.87
Disparities in Health Services for HIV/AIDS, Hepatitis C Virus, and Sexually Transmitted Infections: Role of Substance Abuse Treatment Programs. J Addict Med (2009) 0.87
The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. J Hepatol (2011) 0.86
Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin. Rev Gastroenterol Disord (2004) 0.86
Substance abuse treatment clinician opinions and infectious disease service delivery. J Addict Dis (2009) 0.86
The era of direct-acting antivirals has begun: the beginning of the end for HCV? Semin Liver Dis (2011) 0.86
Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr (2005) 0.85
Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig Dis Sci (2007) 0.85
Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. AIDS (2007) 0.85
Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol (2008) 0.85
Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Dig Dis Sci (2007) 0.84